Previous 10 | Next 10 |
WALTHAM, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busine...
"The time to quit is before you wish you had .” ― Kimberly K. Jones, Sand Dollar Summer Today, we look at a small biotech concern focused on diseases of the central nervous system ((CNS)). The company does not get much coverage yet in the analyst community and the shares h...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red last week, dipping from 3,429.71 points on Monday’s (June 24) open to 3,410.20 points as of 12:14 p.m EDT on Friday (June 28). On Thursday (June 27), Dova Pharmaceuticals (NASDAQ: DOVA ) announced that it received an ...
InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
While cannabis stocks continue their selloff today, biotech stocks are moving higher, with one in particular in the spotlight. On Monday, June 24, NERV stock jumped more than 40% in mid-day trade; this occurred after Minerva Neurosciences (NASDAQ:NERV) said its trial of Seltorexant m...
Minerva Neurosciences (NASDAQ: NERV ) +58% on positive results from a Phase 2b clinical trial, ISM2005 , evaluating seltorexant (MIN-202) in patients with insomnia disorder. More news on: Minerva Neurosciences, Inc., PCM, Inc., Krystal Biotech, Inc., Stocks on the move, ...
Nasdaq has suspended trading in Minerva Neurosciences (NASDAQ: NERV ) pending the release of news. Shares were up 3% at the time. More news on: Minerva Neurosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1, sho...
Call scheduled for 8:30 a.m. Eastern Time on June 24 to review results of successful Phase 2b trial showing achievement of primary and secondary endpoints with potential first-in-class specific orexin- 2 receptor antagonist for the treatment of insomnia Key Opinion Leaders, Dr. Thomas ...
WALTHAM, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securitie...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...